Non-alcoholic fatty liver disease

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced the U.S. availability of Rezdiffra (resmetirom), marking a milestone in the treatment of non-alcoholic steatohepatitis (NASH). This development heralds a …